Ropes & Gray Team Advises Bain Capital in Majority Investment in QuVa Pharma and Acquisition of Healix Assets
Ropes & Gray represented Bain Capital, one of the world's foremost private investment firms, with more than $75 billion under management across several asset classes, in its majority equity commitment to QuVa Pharma, Inc., a newly formed national platform for sterile compounding pharmacy services. QuVa announced Aug. 24 that it had acquired the assets of the 503B Compounding Pharmacy Services Division of Healix, Inc., including its state-of-the-art manufacturing facility. Financial terms of the private transaction were not disclosed.
The Ropes & Gray team was led by private equity partner Neill Jakobe (Chicago) and included private equity partner William Mone (Boston); health care partner Deborah Gersh (Chicago); life sciences partner Gregory Levine (Washington, D.C.); tax partners Aaron Harsh and Amanda Holt (both of Boston); and intellectual property transactions counsel Thomas Burke (New York). The team also included health care associate Elizabeth Whitkin (Boston); and corporate associate Christopher Liedl (Boston).
Click here for more information.